Aripiprazole and ziprasidone are associated with significantly less risk of metabolic disorders and may be preferred in older adults who have diabetes, obesity, or hyperlipidemia. Aripiprazole has the lowest risk of QTc prolongation and may be
preferred in patients who have prolonged QTc interval.
Quetiapine and clozapine are associated with the lowest risk of EPS. Among SGAs, aripiprazole is associated
with the lowest risk of prolactin elevation and sexual side effects and may be preferred in older adults who complain of sexual dysfunction or have osteoporosis.